| abstract |
The present invention preferably relates to CAR, CAR-T and CAR-NK constructs comprising scFv antibody fragments against disease associated antigens or haptens. More preferably, the antigen is a TAA, eg, Trop-2. The construct may be administered to a subject having a disease, such as a cancer, an autoimmune disease, or an immunodeficiency disease, to induce an immune response against the disease associated cells. If the construct binds to a hapten, the subject is first treated with a hapten conjugated antibody that binds to the disease associated antigen. The therapy may be supplemented with other treatments such as weight loss procedures (e.g. surgery, chemotherapy, radiation therapy) or co-administration of other agents. More preferably, administration of the construct is preceded by preadministration of unconjugated antibody that binds to the same disease associated antigen. Most preferably, antibodies to CD74 or HLA-DR are administered to reduce systemic immunotoxicity induced by the construct. [Selected figure] Figure 7 |